Signal transduction pathway targets for anticancer drug discovery

Current Pharmaceutical Design

Volumn 6, Issue 4, 2000, Pages 361-378

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; TRASTUZUMAB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; HUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034080399     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612003400821     Document Type: Review

References (5)

1. Heimbrook, D. C.; Oliff, A. Therapeutic Intervention and Signaling. Curr. Opin. Cell Biol. 1998, 10, 284-288.
2. Leevers, S. J.; Vanhaesebroeck, B.; Waterfield, M. D. Signaling Through Phosphoinositide 3-Kinases: The Lipids Take Centre Stage. Curr. Opin. Cell Biol. 1999, 11, 219-25.
3. Koch, C. A.; Anderson, D.; Moran, M. F.; Ellis, C.; Pawson, T. SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins. Science 1991, 252, 668-674.
4. Hunter, T. Oncoprotein Networks. Cell 1997, 88, 333-46.
5. Carpenter, C.L.; Cantley, L. C. Phosphoinositide Kinases. Curr. Opin. Cell Biol. 1996, 8, 153-158.